Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | CCR2 | P41597 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GFER | P55789 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12594373 | 0.91 | CYP2C9 (0.55) | CYP3A4CCR2CYP2C9NUDT1TNNI3K | |
| SCHEMBL22461745 | 0.89 | CYP3A4 (0.67) | CYP3A4CCR2CYP2C9NUDT1TNNI3K | |
| SCHEMBL12594251 | 0.89 | CYP3A4 (0.63) | CYP3A4CCR2CYP2C9NUDT1TNNI3K | |
| SCHEMBL21325745 | 0.86 | CYP3A4 (0.60) | CYP3A4CCR2CYP2C9NUDT1TNNI3K | |
| SCHEMBL12040686 | 0.86 | CYP3A4 (0.72) | CYP3A4CCR2CYP2C9TNNI3KALDH1A1 | |
| SCHEMBL1762314 | 0.84 | CYP2C9 (0.58) | CYP3A4CCR2CYP2C9NUDT1TNNI3K | |
| SCHEMBL1762423 | 0.84 | CYP2C9 (0.56) | CYP3A4CCR2CYP2C9NUDT1CYP1A2 | |
| SCHEMBL1762385 | 0.84 | CYP3A4 (0.79) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL25023972 | 0.84 | CYP3A4 (0.64) | CYP3A4CCR2CYP2C9NUDT1CYP2C19 | |
| SCHEMBL1762517 | 0.83 | CYP2C9 (0.55) | CYP3A4CCR2CYP2C9NUDT1TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | CYP3A4 3935/4885CCR2 1/4885CYP2C9 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.